Strategic Performance and Operational Context
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
Performance was characterized by a 30% year-over-year reduction in operating expenses, reflecting a strategic shift toward a disciplined operating model where spending is strictly aligned with revenue generation.
Revenue remained flat year-over-year due to approximately $200,000 in booked orders that could not be shipped to the Middle East because of regional conflict in the Strait of Hormuz.
Medical revenue more than doubled year-over-year, driven by early-stage adoption of the CompuFlo system and growing interest from clinicians in complex pain management cases.
The dental business remains the company’s backbone, supported by the expansion of a national ambassador program that has already engaged 73 active ambassadors to drive demos and sales.
Management is focusing on ‘high-volume opportunities’ for CompuFlo placement, noting that each unit can represent $75,000 to $125,000 in annual revenue if utilized for 50 cases per month.
Strategic positioning is shifting toward academic and teaching hospitals, where younger physicians are more likely to adopt new technology and push clinical boundaries.
Outlook and Strategic Roadmap
Management reaffirmed 2026 revenue guidance of $9.8 million to $10.2 million, assuming double-digit year-over-year growth and accelerated CompuFlo adoption.
The company aims to reach cash flow breakeven in early 2027 through continued cost discipline and improved operating leverage from higher-margin medical sales.
A formal re-engagement with Medicare (MACs) is planned for early June 2026 to discuss reimbursement levels based on the current volume of submitted claims.
The strategic roadmap includes a planned submission for a Category I CPT authorization in November 2026, targeting a February 2027 meeting for approval.
International expansion is focused on Tier 1 markets, with product registrations expected in India and Mexico by Q3 2026 and Japan by September 2026.
Financial and Risk Factors
A $2.15 million financing completed in April 2026 strengthened the balance sheet to support sales expansion, inventory, and digital marketing initiatives.
Operating losses narrowed by 58% year-over-year to $828,000, primarily due to structural cost reductions implemented in the prior year.
Inventory levels are being managed carefully to balance capital conservation with the potential for rapid demand spikes if Medicare reimbursement levels improve.
The ongoing Middle East conflict remains a risk factor for international shipping, though a majority of the $200,000 Q1 backlog has already shipped in Q2.
